IGF1R and adrenal cortex carcinoma: Linsitinib, a dual inhibitor of the insulin-like growth factor 1 (IGF1R) and of the insulin receptor (IR), represents the only drug to have entered a phase III trial for ACC patients, but it also yielded disappointing results (24).